英飛特(300582.SZ):副總經理兼CFO張玲豔辭職 由姚永華接任
格隆匯3月2日丨英飛特(300582.SZ)宣佈,公司董事會於2021年2月28日收到公司副總經理、財務負責人(CFO)張玲豔提交的書面辭職報吿,張玲豔因個人原因辭去公司副總經理、財務負責人(CFO)職務,辭職後不在公司擔任其他職務。辭職報吿自送達公司董事會之日起生效。
公司於2021年3月2日召開第三屆董事會第三次會議,審議通過了《關於聘任公司副總經理、財務負責人的議案》。經公司總經理提名、董事會提名委員會審查,公司董事會同意聘任姚永華為公司副總經理、財務負責人(CFO),任期自該次董事會審議通過之日起至第三屆董事會任期屆滿之日止。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.